Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...